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Objective: To compare antipsychotic prescribing patterns in younger (aged 59 years or 
younger) and older (aged 60 years or older) patients with psychotic or mood disorders. 
Method: Pharmacy records of all patients discharged from the Centre for Addiction and 
Mental Health over a 21-month period were reviewed. A total of 1357 patients who were 
prescribed an antipsychotic at the time of their discharge were included in the analysis (956 
with a primary psychotic disorder and 401 with a primary mood disorder). World Health 
Organization-defined daily doses were used as the standardized dosing unit. 
Results: Both in patients with a primary psychotic disorder and in patients with a primary 
mood disorder, the prescribing patterns were similar in older and younger patients, with no 
statistical difference in the proportions receiving first-generation anti psychotics, 
second-generation antipsychotics (SGAs), multiple anti psychotics, or long-acting (depot) 
anti psychotics. Overall, the mean daily antipsychotic doses were lower only in the older 
group of patients with a primary mood disorder. However, the mean dose of SGAs was 
about 30% lower in older patients in both diagnostic groups. Regardless of age, patients 
with a mood disorder were prescribed lower doses of anti psychotics than those with a 
psychotic disorder. 
Conclusions: Our data suggest that older patients are prescribed lower antipsychotic 
dosages primarily when using SGAs. This finding emphasizes the need for dose-finding 
studies asseSSing both the efficacy and the safety of anti psychotics in older patients with a 
psychotic or mood disorder. 
Can J Psychiatry. 2010;55(4):248-254. 
Clinical Implications 
• Older patients with a primary psychotic disorder or a mood disorder may be 
successfully treated with lower doses of antipsychotic drugs. 
• Patients with mood disorders may need lower doses of antipsychotic drugs than those 
with primary psychotic disorders. 
• Antipsychotic dose adjustment may be necessary as patients grow older irrespective 
of their diagnosis. 
Limitations 
• The analysis is based on prescription data. Thus it reflects physician's prescribing 
behaviour, which mayor may not be related to clinical effects. 
• Some clinical characteristics, including duration of treatment, that are expected to 
impact prescribing behaviour were not available. 
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Aging is associated with increased sensitivity to medica-tions. This is thought to be due to a combination of a 
decreased ability ofthe body to eliminate drugs with aging, as 
well as increased sensitivity of the target organs. I,2 The pri-
mary indication for antipsychotic medication is in the man-
agement of schizophrenia and bipolar disorder, both lifelong 
conditions that are associated with a high relapse rate on drug 
discontinuation. The literature on antipsychotic dosing in 
older adults is almost entirely restricted to practice guidelines 
that are largely guided by expert clinical opinion rather than 
empirical data. These guidelines recommend that elderly 
patients should be initiated and maintained on lower doses of 
antipsychotics3.4 owing to greater sensitivity to adverse 
effects. I,2 These recommendations imply that this increased 
sensitivity to drug adverse effects is associated with a parallel 
increased sensitivity to therapeutic effects resulting in lower 
dosing requirements in this older population. However, to 
date, this assertion has not been explicitly tested in prospec-
tive studies. Also, it is unclear whether these recommenda-
tions are routinely followed in clinical practice. Most 
pharmaco-epidemiologic studies of antipsychotic medica-
tions have not explicitly evaluated their use in elderly popula-
tions,5-8 have not compared elderly populations with younger 
populations,9-11 and have not provided specific dosing infor-
mation,9,lo,12 One recent study I 3 has evaluated the effect of age 
on antipsychotic dose in patients with psychotic disorders 
across a broad age range and settings in Japan. In this study, 
prescribed antipsychotic doses increased with age through the 
third decade, subsequently plateaued, and decreased after the 
fifth decade. 13 However, this survey did not include patients 
with mood disorders. Further, prescribed doses reflect various 
direct and indirect local influences such as training and local 
standard of care, This limits the extrapolation of results from 
one community to another. 
We therefore sought to examine the pattern of use for 
antipsychotic medications in a large Canadian psychiatric 
hospitaL The objectives of our study were to compare the 
antipsychotic prescribing patterns in younger (aged 59 years 
or younger) and older (aged 60 years or older) hospitalized 
patients with a psychotic disorder or a mood disorder. Given 
the higher sensitivity to adverse effects of older patients, we 
hypothesized that, compared with younger patients: they 
would be more likely to be prescribed SGAs and less likely to 
be prescribed multiple antipsychotics, clozapine, or depot 
Abbreviations used in this article 
CAMH Centre for Addiction and Mental Health 
DDD defined daily dose 
FGA first-generation antipsychotic 
PORT Patient Outcomes Research Team 
RAI-MH Resident Assessment Instrument-Mental Health 
SGA second-generation antipsychotic 
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antipsychotic formulations; and they would be prescribed 
lower antipsychotic doses. Further, we hypothesized that, 
regardless of age, patients with a primary mood disorder 
would be less likely than patients with a primary psychotic 
disorder to be prescribed FGAs, multiple antipsychotics, 
clozapine, or depot antipsychotic formulations. 
Methods 
Setting and Subjects 
CAMH is a large Canadian psychiatric hospital, fully affili-
ated with the University of Toronto, with more than 600 inpa-
tient beds and about 120 psychiatrists. Patients discharged 
from January 2005 to September 2006 who were prescribed 
an antipsychotic medication at time of discharge were 
included in the analysis. Antipsychotic regimens at discharge 
were chosen as a proxy of the optimal regimen needed for 
therapeutic benefit based on the clinical judgment of the 
treating psychiatrists. Similarly, if a patient was discharged 
on an antipsychotic medication more than once in that period, 
only the data from the most recent discharge were included, 
under the assumption that this would be more likely to repre-
sent optimization of the antipsychotic regimen for the patient. 
Antipsychotics to be used as needed were excluded from the 
analysis. 
Clozapine, olanzapine, quetiapine, and risperidone were the 
4 SGAs available in Canada when our study was conducted. 
All other antipsychotics were classified as FGAs. The unit of 
measurement used for standardizing antipsychotic doses was 
the World Health Organization Collaborating Centre for 
Drug Statistics Methodology system of DOD. The DOD unit 
is the assumed average maintenance dose per day for a drug 
used for its main indication in adults. For example, I DOD 
unit is 300 mg/day for oral chlorpromazine, 5 mg/day for oral 
risperidone, and 10 mg/day for oral olanzapine. It is impor-
tant to note that the DDD units do not imply recommended 
dosing in specific populations, but rather serves as a method 
of standardizing dosage units across agents for the purpose of 
pharmacoepidemiologic studies. 
Primary diagnostic categories (that is, psychotic disorders 
and mood disorders) were based on diagnoses recorded in the 
standardized RAI administered at discharge. 14 Schizophre-
nia, schizoaffective disorder, and psychotic disorder not oth-
erwise specified were classified as psychotic disorders. 
Major depressive disorder, bipolar disorder, and dysthymic 
disorder were classified as mood disorders. Younger patients 
were defined as aged 59 years or younger and older patients 
were defined as aged 60 years and older. This cut-off was 
chosen to reflect the dichotomous detinitions commonly 
used in treatment guidelines. 
Data Analysis 
SPSS version 15 (SPSS Inc, Chicago, IL) for Windows was 
used for the statistical analyses. Differences between groups 
were tested using a Student t test or one-way ANOYA for 
parametric data or chi-square test for categorical variables. A 
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Table 1 Antipsychotic prescription patterns at discharge in patients with a primary psychotic 
disorder diagnosis 
Older group 
Prescription variable ;::60 years 
All antipsychotics, n (%) 105 (100) 
DOD, mean (SO) 1.36 (1.93) 
Monotherapy, n (%) 92 (87.6) 
SGA, n (%) 75 (71.4) 
DOD, mean (SO) 0.96 (0.57) 
FGA, n (%) 17 (16.2) 
DOD, mean (SO) 1.74 (3.28) 
Polytherapy, n (%) 13 (12.4) 
Specific agents 
Clozapine, n (%) 14 (13.3) 
OOO,a mean (SO) 1.35 (0.4) 
Risperidone (oral), n (%) 37 (35.2) 
OOO,b mean (SO) 0.59 (0.39) 
olanzapine (oral), n (%) 25 (23.8) 
DOD," mean (SO) 1.78 (1.26) 
Depot formulations, n (%) 25 (23.8) 
DOD, mean (SO) 2.48 (3.59) 
8400 mg/day. 
b 5 mg/day. 
c 10 mg/day. 
ns = not significant 
P value of 0.05 was considered statistically significant and all 
tests were 2-tailed. Our study was approved by the Research 
Ethics Board of the CAMH and exempted from the require-
ment for informed consent because the study involved 
de-identified data acquired during routine care. 
Results 
During the study period, 2310 patients were prescribed an 
antipsychotic at time of discharge. RAI diagnostic informa-
tion was available for 1549 of these patients, of whom 956 had 
a primary psychotic disorder diagnosis and 401 patients had a 
primary mood disorder diagnosis. The analyses are based on 
1357 patients. Secondary diagnoses in these patients were 
highest for substance use disorders (17.4%), anxiety disorders 
(14.1 %), and cognitive disorders (2.3%). 
Patients With a Primary Psychotic Disorder 
In patients with a primary psychotic disorder, there were no 
differences between the 2 age groups in the proportion of 
those prescribed SGAs or FGAs (Table 1). Likewise, there 
were no significant differences between the proportion of 
patients in each age group prescribed multiple antipsychotics. 
Risperidone was the most commonly used antipsychotic in the 
older group, with olanzapine ranked second. Similar propor-
tions of patients in the 2 groups were prescribed clozapine, as 
250 
Younger group 
<60 years Statistics 
851 (100) 
1.45 (0.86) ns 
717 (84.3) ns 
589 (69.2) ns 
1.37 (0.71) t = 5.63, df = 106, P < 0.001 
128 (15.0) ns 
1.05 (0.83) ns 
134 (15.7) ns 
137 (16.1) ns 
1.47 (0.65) ns 
230 (27.0) ns 
1.15 (0.71) t = 7.13, df= 82, P < 0.001 
308 (36.2) X2 = 6.31, df= 1, P= 0.01 
1.85 (0.86) ns 
184 (21.6) ns 
1.76 (1.09) ns 
were the proportions prescribed depot formulations. Most 
depot formulations were FGAs, with risperidone pro-
longed-release suspension comprising 22.5%. 
Overall, the prescribed antipsychotic doses did not differ sig-
nificantly between younger and older patients (Table I and 
Figure 1). However, when comparing dosing of each 
antipsychotic category, the mean daily dose of SGAs was 
about 30% lower in the older group, compared with the youn-
ger group. Risperidone dosing in particular was lower in the 
elderly group, compared with the younger group. In patients 
prescribed FGAs, there was a large variability of doses in the 
older group (as reflected by the large SD) and the mean doses 
of the 2 groups did not differ significantly (Table I). 
Patients With a Primary Mood Disorder 
In patients with a primary mood disorder, there were similar 
proportions of patients in the older group and younger group 
prescribed FGAs, SGAs, or depot antipsychotic formulations 
(Table 2). None of the older patients with a primary mood 
disorder were prescribed multiple antipsychotics or 
clozapine. Overall, the mean antipsychotic dose was about 
30% lower in the older group than in the younger group 
(Table 2). This was the case primarily with SGAs, whereas 
the dosing for the FGAs was similar between the groups 
(Table 2). 
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Figure 1 Mean total DOD for anti psychotics by age group and diagnostic category 
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The vertical bars represent standard errors, A significant difference in prescribed dose was not found among age decade 
groups in patients with a primary psychotic disorder (n = 956; F = 0.59, df= 6,949, P = 0.73) but was in patients with a primary 
mood disorder (n = 401; F = 2.26, df= 6,394, P = 0.04), using a 1-way ANOVA. 
Comparing Patients With a Primary Mood Disorder or a 
Primary Psychotic Disorder 
When comparing patients with a primary mood or psychotic 
disorder, only 7.7% of patients with a mood disorder were 
receiving an FGA, compared with 16.8% of those with a psy-
chotic disorder (X2 = 27.12, df= 2, P< 0.001). Patients with a 
mood disorder were also less likely to be prescribed multiple 
antipsychotics (8.7%, compared with 15.4%; X2 = 10.75, 
df= 1, P = 0.001), clozapine (1.2%, compared with 15.8%; 
X2= 58.77, df= 1, P< 0.001), and depot formulations (5.0%, 
compared with 21.9%; X2 = 57.35, df = 1, P < 0.001). As illus-
trated in Figure 1, regardless of age, significantly lower total 
daily doses of antipsychotics were prescribed to patients with 
a primary mood disorder than to patients with a psychotic dis-
order (mean [SD] DDD 1.03 [0.85], compared with 1.44 
[1.03]; t= 7.1, df= 1355, P < 0.001). 
Discussion 
We examined the prescribing practices for antipsychotic med-
ications at the time of discharge over a 21-month period in a 
large Canadian academic psychiatric hospital. Contrary to our 
hypothesis, our main findings are irrespective of diagnosis, 
older patients were as likely to receive FGAs, multiple 
antipsychotics, and long-acting injectable (depot) 
antipsychotics as younger patients. The mean daily 
antipsychotic doses were lower in the older group only in 
patients with a primary mood disorder. Consistent with our 
hypothesis, patients with a mood disorder were less likely to 
receive FGAs, multiple antipsychotics, clozapine, or depot 
formulations than those with a psychotic disorder. Also, 
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regardless of age, antipsychotic doses were lower in patients 
with mood disorders than in patients with psychotic 
disorders. 
Very few published studies have specifically evaluated the 
pattern of antipsychotic prescriptions in elderly patients with 
schizophrenia or mood disorders. In one studyl2 from the 
early 1990s (reflecting FGA usage) the prescribing patterns 
in 595 patients were analyzed. Patients with schizophrenia 
aged 56 years and older had reduced odds of receiving doses 
greater than 1000 mg chlorpromazine equivalents per day, 
defined as high antipsychotic doses according to the PORT 
recommendations (OR 0.43,95% CI 0.24 to 0.76).12 Another 
study also found differences in antipsychotic dosing in a 
group of patients with schizophrenia attending a depot 
neuroleptic clinic in 1998. In younger subjects (aged 44 years 
and younger, n = 79) age and doses were not correlated, 
whereas, in subjects aged 45 years and older, they were nega-
tively correlated (r = -0.25, P = 0.02, n = 86). Further, sub-
jects aged 60 years and older received lower daily doses, 
compared with those aged 20 to 40 years (mean [SD] dose, 
mg chlorpromazine equivalents per day: 275 [239], com-
pared with 378 [346]).15 A relation with age was also found in 
a large study that evaluated the quality of oral antipsychotic 
prescribing to patients with schizophrenia treated in the US 
Department of Veteran Affairs, over a 4-month period in 
1999. Among 34 925 outpatients, 47% were receiving FGAs 
and 59% were receiving SGAs. Most patients (63.6%) were 
receiving doses within the range recommended by the PORT, 
with 23.3% receiving lower doses. With a mean age of 52 
(SD 11) years, increasing age was associated with an 
increased likelihood of receiving a dose below the 
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Table 2 Antipsychotic prescription patterns at discharge in pafients with a primary mood 
disorder diagnosis 
Oldergtoup 
Prescription variable ~60 years 
All anti psychotics, n (%) 44 (100) 
DOD, mean (SO) 0.74 (0.71) 
Monotherapy, n (%) 44 (100) 
SGA.n(%) 39 (88.6) 
DOD, mean (SO) 0.72 (0.69) 
FGA,n(%) 5 (11.4) 
DOD, mean (SO) 0.89 (0.91) 
Polytherapy, n (%) 0 
Specific agents 
Clozapine, n (%) 0 
ODD·, mean (SO) -
Depot fonmulations, n (%) 3 (6.8) 
DOD, mean (SO) 1.19 (1.07) 
• 400 mg/day. 
ns = not significant; - = not applicable 
recommended range, and a decreased likelihood of receiving 
multiple antipsychotics (OR 1.3 and 0.93, respectively, for an 
age increment of 5 years).8 In another large survey of 
antipsychotic dosing conducted in Japan, there was an 
inverted U-shaped relation between age and prescribed dose 
across the lifespan, with decreasing doses observed after the 
fifth decade.13 Also, lower doses of antipsychotics were used 
in patients with late-onset schizophrenia and very late-onset 
schizophrenia (onset after age 60 years), compared with 
patients with early-onset schizophrenia. 13 
In contrast to these studies, and clinical practice guideline rec-
ommendations, patients with a primary psychotic disorder in 
our Canadian study did not demonstrate a clear relation 
between older age and lower dosing. As illustrated in Figure 
1, presenting antipsychotic doses by decade, the dosing pat-
tern for patients with a primary psychotic disorder appears 
quite level across the age ranges. Lower doses were only 
detected when specifically evaluating patients receiving 
SGAs, and risperidone in particular. This may reflect either 
clinical efficacy at lower doses or lower tolerability at higher 
doses. Although dosing information was not specified in pre-
vious studies based on class of antipsychotic, a significant 
proportion ofthe antipsychotics prescribed in these older sur-
veys were FGAs. Since these studies were conducted, SGAs 
are used much more extensively: they were the predominant 
agents in our study. It is possible that the older patients receiv-
ing FGAs in our inpatient study are more difficult to treat (for 
example, they have failed to respond to SGAs) and require 
high doses. Thus the absence of a difference in the mean FGA 
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Younger group 
<60 years Statistics 
357 (100) 
. 1.07 (0.86) t = 2.4, df = 399, P = 0.02 
3.22 (90.2) "1..2 = 4.73, df= 1, P= 0.02 
298 (83.5) ns 
1.00 (0.75) t = 2.19, df = 335, P = 0.03 
24 (6.7) ns 
1.05 (0.83) ns 
35 (9.8) "1..2 = 4.73, df= 1, P = 0.02 
5 (1.4) -
1.66 (0.88) -
17 (4.8) ns 
1.77(0.77) ns 
doses of older and younger patients may reflect this clinical 
complexity. 
We had also hypothesized that given the reported enhanced 
sensitivity to adverse effects in older patients, these patients 
would be more likely to be prescribed SGAs and less likely to 
be prescribed multiple antipsychotics, clozapine, or depot 
antipsychotic formulations. However, this was not the case. 
The implication is that older patients treated as inpatients at a 
tertiary psychiatric care centre may be able to tolerate and 
benefit from similar prescribing approaches to those used in 
younger patients. If this is the case, then this observed pre-
scribing practice may have some bearing on the neurobiology 
of the illness in treatment-refractory patients or long-term 
effects of antipsychotic drugs (for example, upregulation of 
dopamine receptors). It also may be that the overall very high 
rate of SGA use and low rate of prescribing multiple 
antipsychotics left little room for differences between the 
groups to emerge. 
The use of SGAs in our patients is consistent with the trends 
in antipsychotic prescribing in the elderly for the entire prov-
ince of Ontario as reported in a study examining the Ontario 
Drug Benefit prescription database for patients aged 65 years 
and older during the years from 1993 to 2002 (over 1.4 mil-
lion people). 8 In addition to the overall increase in 
antipsychotic use (from 2.2% to 3% of the elderly popula-
tion), the use of SGAs increased from no use in 1993 when 
they were not yet available to 82.5% of the antipsychotics 
prescribed in 2002 to this population. Risperidone and 
olanzapine were the most common SGAs prescribed in 2002 
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(accounting for 56.4% and 29.6% of SGA prescriptions, 
respectively). 
Studies published to date have not focused on antipsychotic 
prescribing patterns in patients with primary mood disorders. 
In our study, the antipsychotic prescribing pattern is different 
for patients with mood disorders and for patients with psy-
chotic disorders in that lower antipsychotic doses were pre-
scribed to those with mood disorders (Figure 1 illustrates this 
difference across the entire age range). Further, in patients 
with mood disorders, doses peak during the fourth decade. 
Patients with mood disorders were also less likely to be pre-
scribed FGAs, multiple antipsychotics, clozapine, or depot 
formulations. This appears to reflect a more cautious use of 
antipsychotic medications in patients who do not have a pri-
mary psychotic disorder. Alternatively, this finding may 
imply reduced requirements for antipsychotic drugs in 
patients with mood disorders. Despite a recent trend of using 
SGAs for mood disorders,16,17 there are no published formal 
studies that compare therapeutic doses between psychotic and 
mood disorders. However, one recent systematic review 
shows that patients with bipolar disorder, especially bipolar 
depression, are more susceptible to extrapyramidal side 
effects than those with schizophrenia. 18 These findings, 
including ours, emphasize the need for further investigations 
to address the appropriate dosing of antipsychotics in younger 
and older patients with mood disorders. 
Our study has both strengths and limitations. It has a relatively 
large sample in which we were able to compare antipsychotic 
prescribing patterns in different age and diagnostic groups, 
including class of antipsychotic (SGAs and FGAs) and use of 
depot antipsychotic preparations. However, as with most pre-
scription database studies, we could not control for clinical 
variables other than age and diagnosis. Specifically, we could 
not link prescription patterns to clinical presentations and 
outcomes. 
Conclusions 
Our data suggest that older patients are prescribed lower 
antipsychotic dosages primarily when using SGAs and that, 
regardless of age, patients with mood disorders are prescribed 
lower doses of antipsychotics than patients with psychotic 
disorders. These findings emphasize the need for dose-
finding studies assessing both the efficacy and the safety of 
antipsychotics in older patients with psychotic or mood 
disorders. 
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Resume: Les modeles de prescription d'antipsychotiques sont ils-differents 
pour les jeunes adultes et les adultes ages? Un sondage de 1357 patients 
psychiatriques hospitalises it Toronto 
Objectif : Comparer les modeles de prescription d'antipsychotiques a des patients jeunes 
(de 59 ans ou moins) et des patients ages (de 60 ans ou plus) souffrant de troubles 
psychotiques ou de I'humeur. 
Methode: Les dossiers pharmaceutiques de tous les patients ayant re~u leur conge du 
Centre de toxicomanie et de sante mentale sur une periode de 21 mois ont ete etudies. Un 
total de 1357 patients a qui on avait prescrit un antipsychotique au moment de leur conge 
etait indus dans I'analyse (956 souffrant d'un trouble psychotique primaire et 401 souffrant 
d'un trouble de I'humeur primaire). Des doses quotidiennes definies par l'Organisation 
mondiale de la sante ont ete utilisees comme unite de posologie normalisee. 
Resultats : Tant chez les patients souffrant d'un trouble psychotique primaire que chez ceux 
souffrant d'un trouble de I'humeur primaire, les modeles de prescription etaient semblables 
pour les patients jeunes et ages, et il n'y avait aucune difference statistique dans les 
proportions qui recevaient des antipsychotiques de la premiere generation, des 
antipsychotiques de la deuxieme generation (ADG) des antipsychotiques multiples, ou des 
antipsychotiques a action prolongee. En general, les doses moyennes quotidiennes 
d'antipsychotiques etaient plus faibles seulement dans Ie groupe des patients ages souffrant 
d'un trouble de I'humeur primaire. Toutefois, la dose moyenne d'ADG etait environ 30 % plus 
faible pour les patients ages des deux groupes diagnostiques. Sans egard a rage, on 
prescrivait aux patients souffrant d'un trouble de I'humeur des doses plus faibles 
d'antipsychotiques qu'a ceux souffrant d'un trouble psychotique. 
Conclusions: Nos donnees suggerent qu'on prescrit des doses plus faibles 
d'antipsychotiques aux patients ages, surtout quand on utilise des ADG. Ce resultat souligne 
la necessite d'etudes destinees a I'etablissement de la posologie qui evaluent I'efficacite et 
I'innocuite des antipsychotiques pour les patients ages souffrant d'un trouble psychotique ou 
de I'humeur. 
.. La Revue canadienne de psychiatrie, vol 55, no 4, avril 2010 
